Abstract
The authors carried out a 1-year, randomized, placebo-controlled trial of idebenone in 29 patients with Friedreich ataxia. They found significant reductions of interventricular septal thickness and left ventricular mass in the idebenone group vs the placebo group, with no improvement in other heart ultrasound measures or neurologic condition. The absolute cardiac changes were modest, but the findings suggest that larger trials should assess whether idebenone reduces ventricular hypertrophy in patients with Friedreich ataxia.
Original language | English |
---|---|
Pages (from-to) | 1676-1679 |
Number of pages | 4 |
Journal | Neurology |
Volume | 60 |
Issue number | 10 |
Publication status | Published - May 27 2003 |
ASJC Scopus subject areas
- Neuroscience(all)